Inhibikase CFO Joseph Frattaroli to retire; Garth Lees-Rolfe promoted as successor

Inhibikase Therapeutics, Inc.

Joseph Frattaroli to retire as CFO effective March 31, 2024; vested stock option exercise period extended.
Garth Lees-Rolfe, current VP of Finance since Nov 2022, will become CFO upon Frattaroli's retirement.
Lees-Rolfe previously VP Finance at F-Star and spent 16 years in public practice, including at Ernst & Young.
Retirement is not due to any disagreement with the Company; transition is planned and orderly.
Compensation for Lees-Rolfe as CFO not yet determined; to be disclosed in a future 8-K amendment.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joseph Frattaroli

Chief Financial Officer

IKT · Inhibikase Therapeutics, Inc.

Effective: 2024-03-31
Successor: Garth Lees-Rolfe
Filed: January 16, 2024, 6:59 PM ET

Joseph Frattaroli provided notice to the Board of Directors (the “Board”) of Inhibikase Therapeutics, Inc. (the “Company”) of his intention to retire as Chief Financial Officer of the Company, effective at the end of the first quarter of 2024 or March 31, 2024.

Appointed

Garth Lees-Rolfe

Chief Financial Officer

IKT · Inhibikase Therapeutics, Inc.

Effective: 2024-03-31
Filed: January 16, 2024, 6:59 PM ET

The Board will appoint Garth Lees-Rolfe to serve as Chief Financial Officer of the Company upon Mr. Frattaroli’s retirement and until the earliest of his removal, termination, or resignation from such office.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Frattaroli departed as Chief Financial Officer at Inhibikase Therapeutics, Inc..

Action: retire
Role: Chief Financial Officer

Exact text from the filing

Joseph Frattaroli provided notice to the Board of Directors (the “Board”) of Inhibikase Therapeutics, Inc. (the “Company”) of his intention to retire as Chief Financial Officer of the Company, effective at the end of the first quarter of 2024 or March 31, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Garth Lees-Rolfe was appointed as Chief Financial Officer at Inhibikase Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

The Board will appoint Garth Lees-Rolfe to serve as Chief Financial Officer of the Company upon Mr. Frattaroli’s retirement and until the earliest of his removal, termination, or resignation from such office.

View on SEC.gov

Inhibikase Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-008593

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.